Anzeige
Erschienen in:
01.03.2010 | Nephrology - Original Paper
Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells
Erschienen in: International Urology and Nephrology | Ausgabe 1/2010
Einloggen, um Zugang zu erhaltenAbstract
Introduction
Vitamin D and its analogues proved to exert immunomodulatory effects. Paricalcitol is a vitamin D analogue that is safe. It has been used for years in the treatment of secondary hyperparathyroidism in hemodialysis patients and, importantly, it is less calcemic than vitamin D. In this study the immunomodulatory/anti-inflammatory properties of paricalcitol were evaluated in vitro.
Subject and methods
Ten healthy volunteers enrolled into the study. Peripheral blood mononuclear cells (PBMC) at a concentration of 106 cells per well were cultured for 48 h in the presence or not of lipopolysaccharide (LPS) (100 ng/ml) and in the presence or not of paricalcitol (10−8 M). TNF-α and IL-8 were measured in the supernatants by ELISA.
Results
Basal TNF-α concentration (50.3 ± 22 pg/ml) was reduced by paricalcitol (44.1 ± 23.2 pg/ml). LPS increased TNF-α concentration (150.0 ± 81.7 pg/ml), but paricalcitol reduced it (121.1 ± 69.0 pg/ml). The effect of paricalcitol on IL-8 production was more profound. Basal IL-8 concentration (1926 ± 455 pg/ml) was reduced by paricalcitol (1273 ± 472 pg/ml). LPS increased IL-8 concentration (2361 ± 385 pg/ml), but paricalcitol returned it to its basal level (1849 ± 417 pg/ml).
Conclusion
The in vitro inhibition of transforming growth factor alpha and interleukin 8 by paricalcitol confirms the immunomodulatory properties of this vitamin D analogue.